1. Home
  2. SCYX vs NEPH Comparison

SCYX vs NEPH Comparison

Compare SCYX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$2.97

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Logo Nephros Inc.

NEPH

Nephros Inc.

SELL

Current Price

$3.02

Market Cap

35.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SCYX
NEPH
Founded
1999
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
35.3M
IPO Year
2014
2004

Fundamental Metrics

Financial Performance
Metric
SCYX
NEPH
Price
$2.97
$3.02
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
★ $32.67
$6.08
AVG Volume (30 Days)
59.4K
★ 63.7K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
★ 1000.00
EPS
N/A
★ 0.17
Revenue
$257,000.00
★ $18,789,000.00
Revenue This Year
N/A
$17.81
Revenue Next Year
$977.86
$15.90
P/E Ratio
★ N/A
$18.00
Revenue Growth
N/A
★ 32.67
52 Week Low
$0.66
$2.66
52 Week High
$6.09
$6.42

Technical Indicators

Market Signals
Indicator
SCYX
NEPH
Relative Strength Index (RSI) 26.17 40.72
Support Level $0.66 $2.80
Resistance Level $4.15 $3.18
Average True Range (ATR) 0.25 0.24
MACD -0.04 0.01
Stochastic Oscillator 4.17 35.63

Price Performance

Historical Comparison
SCYX
NEPH

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: